Myra Vision, a privately held portfolio company of Shifamed LLC, is developing a novel technology that is designed to allow safe outflow control to achieve maximum reduction of intraocular pressure (IOP) while also reducing complexity and complication rates.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/26/23 | $25,000,000 | Series B |
Cormorant Asset Management PA MedTech VC Fund Shifamed Angel Investors The Capital Partnership | undisclosed |
